SGLT2 | Jotup

Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on:

Giovedì, Maggio 9, 2024

RADNOR, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced financial results for the first quarter ending March 31, 2024, and provided a corporate update.

Key Points:

ET –
RADNOR, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced financial results for the first quarter ending March 31, 2024, and provided a corporate update.
General and Administrative (G&A) expenses were $4.6 million for the quarter ended March 31, 2024, compared to $2.6 million for the quarter ended March 31, 2023.
Total other income, net was $3.9 million for the quarter ended March 31, 2024, compared to $2.3 million for the quarter ended March 31, 2023.
Net loss was $31.5 million for the quarter ended March 31, 2024, compared to $12.6 million for the quarter ended March 31, 2023.

The Lee Health Heart Institute Achieves Most Abstract Acceptance at the Annual American College of Cardiology Conference

Retrieved on:

Lunedì, Aprile 15, 2024

Cardiomyopathy, American College, Health promotion, ACC, Cardiovascular disease, Woman, Cardiac rehabilitation, Moyamoya disease, Abstract, Cardiology, Death, Research, Patient, Parenting, SGLT2, Physician, Heart failure, Medical device

Advancements in research and technology learned at the annual conference will help Lee Health Heart Institute physicians stay at the forefront of cutting-edge practices, ultimately enhancing patient outcomes and strengthening cardiovascular care in Southwest Florida and beyond.

Key Points:

Advancements in research and technology learned at the annual conference will help Lee Health Heart Institute physicians stay at the forefront of cutting-edge practices, ultimately enhancing patient outcomes and strengthening cardiovascular care in Southwest Florida and beyond.
“The Lee Health Heart Institute is not only dedicated to treating cardiovascular disease, but also to finding progressive solutions and advancements to keep the community as heart healthy as possible.
Based at HealthPark Medical Center, the Lee Health Heart Institute is the largest heart program in Southwest Florida.
To learn more about the Lee Health Heart Institute, please visit www.leehealth.org .

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

Retrieved on:

Lunedì, Marzo 25, 2024

In a post-hoc analysis of data from the 10,584 patients in the SCORED Phase 3 clinical trial, 213 all-cause stroke events occurred, including 29 (13.6%) fatal events.

Key Points:

In a post-hoc analysis of data from the 10,584 patients in the SCORED Phase 3 clinical trial, 213 all-cause stroke events occurred, including 29 (13.6%) fatal events.
Sotagliflozin reduced the risk of all-cause stroke by 34%, with 1.2 events per 100 patient-years in the sotagliflozin group and 1.8 events per 100 patient-years in the placebo group.
Similarly, sotagliflozin reduced the risk of ischemic stroke by 32%, with 0.8 events per 100 patient-years in the sotagliflozin group and 1.2 events per 100 patient-years in the placebo group.
Candidate, University of Michigan, Ann Arbor, Michigan
Study researchers found that sotagliflozin inhibits platelet activation through simultaneously targeting SGLT1 and SGLT2.

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on:

Giovedì, Marzo 21, 2024

RADNOR, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced financial results for the fourth quarter and full year ending December 31, 2023, and provided a corporate update.

Key Points:

R&D expenses for the quarter ended December 31, 2023 were $23.7 million, compared to $7.8 million for the quarter ended December 31, 2022.
G&A expenses were $4.0 million for the quarter ended December 31, 2023, compared to $2.2 million for the quarter ended December 31, 2022.
Total other income, net was $3.3 million for the quarter ended December 31, 2023, compared to $0.9 million for the quarter ended December 31, 2022.
Net loss was $24.4 million for the quarter ended December 31, 2023, compared to $9.1 million for the quarter ended December 31, 2022.

Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D

Retrieved on:

Lunedì, Marzo 18, 2024

Patients treated with lanifibranor in combination with empagliflozin maintained a stable weight throughout the 24 weeks study, addressing the moderate, metabolically healthy, weight gain that has been observed in some patients treated with lanifibranor.

Key Points:

Patients treated with lanifibranor in combination with empagliflozin maintained a stable weight throughout the 24 weeks study, addressing the moderate, metabolically healthy, weight gain that has been observed in some patients treated with lanifibranor.
The treatment with lanifibranor 800mg/once daily alone or in combination with empagliflozin for 24 weeks was well tolerated, with no safety concerns reported.
The trial is double-blind for the placebo arm and lanifibranor (800mg daily) arm, and open-label for the combination of lanifibranor (800mg daily) and empagliflozin (10 mg daily) arm.
More details on these results are expected to be presented in upcoming scientific conferences and submitted for publication.

IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon

Retrieved on:

Giovedì, Marzo 14, 2024

For several years, Spherix Global Insights has been closely tracking the IgAN market and recently released its fourth annual US patient chart audit study.

Key Points:

For several years, Spherix Global Insights has been closely tracking the IgAN market and recently released its fourth annual US patient chart audit study.
Spherix is the leading authority on IgAN market dynamics and will continue to provide insight into how nephrologists are treating and approaching care for their IgAN patients.
Patient Chart Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits.
Insights reveal the “why” behind treatment decisions, include year over year trending to quantify key aspects of market evolution, and integrate specialists’ attitudinal & demographic data to highlight differences between stated and actual treatment patterns.

Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D

Retrieved on:

Mercoledì, Marzo 13, 2024

Q&A, Webcast, Patient, SGLT2, MASH, T2D, Euronext Paris, NASH

Daix (France), Long Island City (New York, United States), March 13, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, and other diseases with significant unmet medical needs, will hold an investor conference on Tuesday, March 19, to share the results of the LEGEND Phase II trial, a placebo-controlled, study evaluating lanifibranor alone and in combination with the SGLT2 inhibitor empagliflozin in patients with MASH/NASH and type 2 diabetes (T2D).

Key Points:

Daix (France), Long Island City (New York, United States), March 13, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, and other diseases with significant unmet medical needs, will hold an investor conference on Tuesday, March 19, to share the results of the LEGEND Phase II trial, a placebo-controlled, study evaluating lanifibranor alone and in combination with the SGLT2 inhibitor empagliflozin in patients with MASH/NASH and type 2 diabetes (T2D).
The Company will host a conference call and webcast, followed by a Q&A session, on Tuesday, March 19, 2024, at 8:00 am (New York), 1:00 pm (Paris).
In order to participate to the conference call, please register at the following link: https://register.vevent.com/register/BI334d62953abb41cea27de99dc5da974c .
The live webcast will be available here and on the “ Investor Presentations ” page of the Inventiva website, with the recording and presentation available following the event.

Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications

Retrieved on:

Lunedì, Febbraio 26, 2024

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the publication of preclinical research related to Tenaya’s small molecule inhibitors of histone deacetylase 6 (HDAC6), including TN-301, in the February 26, 2024, issue of Nature Communications. The article, titled “Targeting HDAC6 to Treat Heart Failure with Preserved Ejection Fraction in Mice,” details the potential of inhibiting HDAC6 for the treatment of Heart failure with preserved ejection fraction (HFpEF), a form of heart failure that effects more than three million people in the U.S. alone1.

Key Points:

The article, titled “Targeting HDAC6 to Treat Heart Failure with Preserved Ejection Fraction in Mice,” details the potential of inhibiting HDAC6 for the treatment of Heart failure with preserved ejection fraction (HFpEF), a form of heart failure that effects more than three million people in the U.S. alone1.
Tenaya’s highly selective small molecule inhibitors of the enzyme HDAC6 were discovered using the company’s modality-agnostic target discovery and validation capabilities.
For preclinical studies, Tenaya researchers used TYA-018, an HDAC6 inhibitor structurally and functionally similar to the company’s clinical candidate, TN-301.
The selective effects of HDAC6 inhibition were reaffirmed through genetic deletion studies, in which treatment of Hdac6 knockout mice did not display any of the beneficial effects that wild-type HFpEF mice did following treatment.

FARXIGA Market Insights and Advanced Forecast Report Reveal Critical Developments in Myocardial Infarction Treatment by 2032 - ResearchAndMarkets.com

Retrieved on:

Martedì, Marzo 5, 2024

Health, Pharmaceutical, Research, Growth, SWOT, EU4, Myocardial infarction, Patient, Clinical trial, SGLT2, Heart, Closer, Pharmaceutical industry

The "FARXIGA Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "FARXIGA Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering.
The comprehensive new report detailing FARXIGA's impact and projected growth in the myocardial infarction treatment landscape over the next decade is now available, offering crucial insights into the medication's effectiveness, development, and market projection through 2032.
The report deep dives into FARXIGA's (dapagliflozin) market potential, with its mechanism of action against myocardial infarction extensively analyzed.
FARXIGA stands in the spotlight, with potential new applications poised to further establish its position in the treatment regimen for myocardial infarction.

JARDIANCE Market Size, Forecast, and Emerging Insights, 2019-2023 and 2024-2032: Focus on 7MM - United States, Germany, France, Italy, Spain, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on:

Venerdì, Marzo 1, 2024

Further, it also consists of future market assessments inclusive of the JARDIANCE market forecast analysis for myocardial infarction in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in myocardial infarction.

Key Points:

Further, it also consists of future market assessments inclusive of the JARDIANCE market forecast analysis for myocardial infarction in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in myocardial infarction.
JARDIANCE (Empagliflozin) is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for glucose re-absorption in the kidney.
The report also highlights the JARDIANCE research and development activities in myocardial infarction across the United States, Europe and Japan.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of JARDIANCE in myocardial infarction.